Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Behnam Badie

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
The New England Journal of Medicine|December 29, 2016
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyChristine E Brown, Darya Alizadeh, Renate Starr, et al.
Neuro-Oncology|January 31, 2022
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastomaChristine E Brown, Analiz Rodriguez, Joycelynne Palmer, et al.
Nature Medicine|March 22, 2024
Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialChristine E Brown, Jonathan C Hibbard, Darya Alizadeh, et al.
Research Square|November 14, 2023
Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysisLeo Wang, Angela Taravella Oill, M Blanchard, et al.
Nature Medicine|March 7, 2024
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialChristine E Brown, Jonathan C Hibbard, Darya Alizadeh, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
The New England Journal of Medicine|December 29, 2016
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell TherapyChristine E Brown, Darya Alizadeh, Renate Starr, et al.
Neuro-Oncology|January 31, 2022
Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastomaChristine E Brown, Analiz Rodriguez, Joycelynne Palmer, et al.
Nature Medicine|March 22, 2024
Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialChristine E Brown, Jonathan C Hibbard, Darya Alizadeh, et al.
Research Square|November 14, 2023
Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysisLeo Wang, Angela Taravella Oill, M Blanchard, et al.
Nature Medicine|March 7, 2024
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trialChristine E Brown, Jonathan C Hibbard, Darya Alizadeh, et al.
Pageof 10